首页 > 抗体蛋白 > 抗体
PE anti-mouse IL-6 Antibody
产品名称:
PE anti-mouse IL-6 Antibody
产品类别:
抗体
产品编号:
504503
产品应用:
504503
[价格]
规格 价格 库存
25µg ¥ 1152 1

产品详情

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
COS-7-expressed, recombinant mouse IL-6
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested

Recommended Usage

The MP5-20F3 antibody reacts with mouse interleukin-6 (IL-6). The MP5-20F3 antibody can neutralize the bioactivity of natural or recombinant IL-6. Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 ?g per 106 cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

ELISA Capture1-3,11 or ELISPOT Capture4,5: The purified MP5-20F3 antibody is useful as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated MP5-32C11 antibody (Cat. No. 504602) as the detecting antibody and recombinant mouse IL-6 (Cat. No. 575709)?as the standard. The Ultra-LEAF? purified antibody is suggested for ELISPOT capture.

Flow Cytometry: The fluorochrome-labeled MP5-20F3 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IL-6 -producing cells within mixed cell populations. For intracellular cytokine staining protocol, please visit www.biolegend.com and click on the support section.

Neutralization1-2,8-10: The Ultra-LEAF? purified antibody (Endotoxin <0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for neutralization of mouse IL-6 bioactivity in vivo and in vitro (Cat. No. 504506).

Additional reported applications (for relevant formats of this clone) include: In Vivo Capture7, and immunohistochemical staining (paraformaldehyde-fixed/saponin-treated6, and acetone-fixed frozen tissue sections13, 14).

Note: For testing mouse IL-6 in serum, plasma or supernatant, BioLegend's ELISA Max? Sets (Cat. No. 431301 to 431306) are specially developed and recommended.

Application References

(PubMed link indicates BioLegend citation)
  1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA Capture, Neut)
  2. Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA Capture, Neut)
  3. Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA Capture)
  4. Fujihashi K, et al. 1991. J. Immunol. Meth. 160:181. (ELISPOT Capture)
  5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT Capture)
  6. Litton M, et al. 1994. J. Immunol Meth. 175:47. (IHC)
  7. Finkelman F, et al. 2003. Curr. Prot. Immunol. John Wiley & Sons, New York. Unit 6.28. (In Vivo Capture)
  8. Starnes HF Jr, et al. 1990. J. Immunol. 145:4185. (Neut)
  9. Riedemann NC, et al. 2003. J. Immunol. 170:503. (Neut)
  10. Rochman I, et al. 2005. J. Immunol. 174:4761. (Neut)
  11. O'Connell PJ, et al. 2006. Blood 107:1010. (ELISA Capture)
  12. Ozeki Y, et al. 2010. Int. Immunol. 22:179. PubMed
  13. Galie M, et al. 2005. Carcinogenesis 26:1868 (IHC)
  14. Schone MP, et al. 2000. J Immunol 165:6583 (IHC)
  15. Keswani T, et al. 2014. Exp Parasitol. 141:82. PubMed
  16. Notley CA, et al. 2015. J Immunol. 194:1621. PubMed
Product Citations
  1. Castoldi ?, et al. 2020. Nat Commun. 3.310416667. PubMed
  2. Prystaz K, et al. 2018. Am J Pathol. 188:474. PubMed
  3. Jones N, et al. 2021. Nat Commun. 12:1209. PubMed
  4. Kuwahara M, et al. 2014. Nat Commun. 5:3555. PubMed
  5. Jin Q, et al. 2022. Drug Des Devel Ther. 16:3297. PubMed
  6. Wang F, et al. 2021. Cell Mol Gastroenterol Hepatol. 13:257. PubMed
  7. Yu C, et al. 2015. J Immunol. 195: 3890 - 3900. PubMed
  8. Forbester JL, et al. 2020. J Virol. 94:. PubMed
  9. Shiomi A, et al. 2014. J Immunol. 193:849. PubMed
  10. Piliponsky AM, et al. 2019. Nat Immunol. 0.922916667. PubMed
  11. Zhu M, et al. 2015. J Immunol. 195: 4492 - 4502. PubMed
  12. Meher A, et al. 2014. Am J Pathol. 184:3130. PubMed
  13. Cohen M et al. 2018. Cell. 175(4):1031-1044 . PubMed
  14. Rosser EC, et al. 2020. Cell Metabolism. 31(4):837-851. PubMed
  15. Wright JA, et al. 2021. Front Immunol. 12:705307. PubMed
  16. Li C, et al. 2017. Nat Commun. 8:14275. PubMed
  17. Mogilenko DA et al. 2019. Cell. 177(5):1201-1216 . PubMed
  18. Lyons DO, et al. 2018. PLoS One. 13:e0207704. PubMed
  19. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
RRID
AB_315337 (BioLegend Cat. No. 504503) AB_315338 (BioLegend Cat. No. 504504)

Antigen Details

Structure
Neuropoietic cytokine family; 22-29 kD (Mammalian)
Bioactivity
Hematopoiesis; antigen-specific immune responses, inflammatory reactions; acute phase reaction
Cell Sources
T cells, B cells, macrophages, bone marrow stromal cells, fibroblasts, keratinocytes, mesangium, astrocytes, endothelial cells
Cell Targets
T cells, B cells, hepatocytes, cholinergic neurons
Receptors
Heterodimer IL-6Rα (CD126)/IL-6Rβ (CD130; gp130)
Biology Area
Immunology, Innate Immunity
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. Hirano T. 1998. Intl. Rev. Immunol. 16:249.
3. Patterson P. 1992. Curr. Opin. Neurobiol. 2:94.
4. Van Oers M, et al. 1993. Ann. Hematology 66:219.

Regulation
Upregulated by IL-1, TNF, PDGF, IFN-β, TNF-α, NGF, IL-17; downregulated by glucocorticoids IL-4, TGF-β
Gene ID
16193 View all products for this Gene ID
UniProt
View information about IL-6 on UniProt.org

联系我们

TEL:021-34661275  点击拨打热线